Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 64-67

Effect of Antiretroviral Therapy on the Incidence of Bacterial Pneumonia in Patients with Advanced HIV Infection

JEFFREY H. SULLIVAN, RICHARD D. MOORE, JEANNE C. KERULY, and RICHARD E. CHAISSON

Johns Hopkins School of Medicine, Baltimore, Maryland

To determine the relationship of combination antiretroviral therapy and bacterial pneumonia, we assessed incidence of and risk factors for bacterial pneumonia in 1,898 human immunodeficiency virus (HIV)-infected patients with CD4 cell counts < 200/mm³ followed in the Johns Hopkins HIV clinic between 1993 and 1998. A total of 352 episodes of bacterial pneumonia occurred during 2,310 patient-years of follow-up. Incidence of bacterial pneumonia decreased from 22.7 episodes/100 person-years (py) in the first half of 1993 to 12.3 episodes/100 py in the first half of 1996, reaching a nadir of 9.1 episodes/100 py in the second half of 1997 (p < 0.05). The use of protease inhibitor-containing regimens was associated with a decreased risk of bacterial pneumonia (risk ratio [RR] 0.55, 95% CI 0.31 to 0.94). Lower CD4 cell counts (RR 2.22, 95% CI 1.54 to 3.18), injection drug use as HIV transmission category (RR2.0, 95% CI 1.43 to 2.76), and prior Pneumocystis carinii pneumonia (RR 3.88, 95% CI 1.65 to 9.16) were also significantly associated with bacterial pneumonia. Trimethoprim-sulfamethoxazole and macrolide use were not significantly associated with risk of bacterial pneumonia. There has been a dramatic decline in the incidence of bacterial pneumonia resulting from the use of combination antiretroviral therapy containing protease inhibitors.

This article has been cited by other articles:

				F. M. Gordin, M. P. Roediger, P.-M. Girard, J. D. Lundgren, J. M. Miro, A. Palfreeman, M. C. Rodriguez-Barradas, M. J. Wolff, P. J. Easterbrook, K. Clezy, et al. Pneumonia in HIV-infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 630 - 636. [Abstract] [Full Text] [PDF]

				C. Steele, L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. E. Shellito, and J. K. Kolls Alveolar Macrophage-mediated Killing of Pneumocystis carinii f. sp. muris Involves Molecular Recognition by the Dectin-1 {beta}-Glucan Receptor J. Exp. Med., December 1, 2003; 198(11): 1677 - 1688. [Abstract] [Full Text] [PDF]

				S H Allen, P Brennan-Benson, M Nelson, D Asboe, M Bower, B Azadian, B Gazzard, and J Stebbing Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era Postgrad. Med. J., December 1, 2003; 79(938): 691 - 694. [Abstract] [Full Text] [PDF]

				C. W. Brecher, G. Aviram, and P. M. Boiselle CT and Radiography of Bacterial Respiratory Infections in AIDS Patients Am. J. Roentgenol., May 1, 2003; 180(5): 1203 - 1209. [Full Text] [PDF]

				K. M. O'Neil The Changing Landscape of HIV-Related Lung Disease in the Era of Highly Active Antiretroviral Therapy Chest, September 1, 2002; 122(3): 768 - 771. [Full Text] [PDF]

				A. J. Wolff and A. E. O'Donnell Pulmonary Manifestations of HIV Infection in the Era of Highly Active Antiretroviral Therapy Chest, December 1, 2001; 120(6): 1888 - 1893. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788. [Full Text] [PDF]

				Antiretroviral Therapy Reduces Risk for Bacterial Pneumonia Journal Watch Infectious Diseases, August 24, 2000; 2000(824): 11 - 11. [Full Text]